Welcome to our dedicated page for Nanovibronix news (Ticker: NAOV), a resource for investors and traders seeking the latest updates and insights on Nanovibronix stock.
NanoVibronix Inc. (NAOV) specializes in pioneering ultrasound-based medical devices for noninvasive pain management and infection prevention. This page aggregates official company announcements and verified news about therapeutic innovations, financial performance, and strategic partnerships.
Investors and healthcare professionals will find timely updates on FDA clearances, clinical trial results, and market expansions. Our curated collection includes earnings reports, product launch details, and research breakthroughs—all essential for tracking NAOV's position in the medical technology sector.
Key content categories include regulatory milestones for devices like UroShield®, financial disclosures, and partnership announcements with healthcare distributors. Bookmark this page to monitor how NAOV's low-intensity ultrasound technology addresses critical needs in wound care and catheter-associated infections.
NanoVibronix (NASDAQ: NAOV), a medical technology company focused on non-invasive therapeutic devices, has successfully regained full compliance with Nasdaq listing requirements. The company received formal notification from Nasdaq on April 9, 2025, confirming it has met all criteria for continued listing on The Nasdaq Capital Market, including the critical $1.00 bid price and $2.5 million stockholders' equity requirements.
The previously disclosed listing concern has been resolved, though the company will remain under a Mandatory Panel Monitor until April 9, 2026.
NanoVibronix (NASDAQ: NAOV) has renewed and expanded its exclusive three-year distribution agreement with Dukehill Healthcare for its UroShield device across all Australian States. The agreement, previously focused on Queensland and New South Wales, now extends to South Australia and Victoria following increased healthcare facility inquiries.
The expansion comes after the publication of an independent study highlighting UroShield's effectiveness in reducing catheter-associated complications and improving patient outcomes. Dukehill will showcase UroShield at the 33rd National Conference on Incontinence in Hobart in May 2025, where clinicians will discuss the study findings.
NanoVibronix (NASDAQ: NAOV) announced the publication of an independent health service study of its UroShield® device in The Australian and New Zealand Continence Journal. The study demonstrated significant improvements in patient care and cost reduction for those with indwelling urinary catheters.
Key findings include:
- 86% reduction in UTI incidence
- 70% reduction in catheter blockages
- 82.8% decrease in bladder irrigations
- 52.3% reduction in catheter changes
- 63.5% reduction in resource costs over 5 months
The study, conducted by a New Zealand District Nursing Service, highlighted UroShield's effectiveness in preventing catheter-associated urinary tract infections (CAUTIs) and improving patient comfort while reducing healthcare provider costs through decreased nursing time and fewer interventions.
NanoVibronix (NASDAQ: NAOV), a medical technology company focused on non-invasive therapeutic devices, has announced a 1-for-11 reverse stock split effective March 13, 2025. The stock will begin trading on a split-adjusted basis on March 14, 2025, maintaining its NASDAQ symbol NAOV.
The reverse split, approved by stockholders on February 24, 2025, will reduce outstanding shares from 8,716,327 to approximately 792,394. The conversion will be automatic, with fractional shares rounded up to the nearest whole number. The split will not alter stockholders' percentage ownership in the company.
Proportional adjustments will be made to equity awards, warrants, and other convertible securities. The company's common stock will trade under a new CUSIP number: 63008J702.
NanoVibronix (NASDAQ: NAOV), a medical technology company focused on non-invasive therapeutic devices, has completed the acquisition of ENvue Medical Holdings Corp., a private company specializing in enteral feeding solutions. The strategic acquisition aims to strengthen the combined company's market position in enteral feeding technology and therapeutic medical devices.
The merger is expected to leverage ENvue's proprietary technology alongside NanoVibronix's existing portfolio, creating a broader commercial platform with enhanced distribution and operational efficiencies. The combined entity will focus on addressing patient safety challenges in enteral feeding while expanding market reach in the medical device sector.
NanoVibronix (NASDAQ: NAOV) has completed the design phase for its next-generation PainShield® and UroShield® devices through a third-party contractor in December 2024. The new prototypes aim to reduce assembly costs and improve user experience.
Key design updates include: an additional therapy mode for enhanced efficacy, future-proofed componentry ensuring availability throughout manufacturing, streamlined software for better performance, and improved user interface with USB-C connectors. For the UroShield® model, a single lead design has been implemented to simplify device setup.
The company is now advancing to the validation and testing phase based on received feedback and protocols. These developments represent a significant milestone in NanoVibronix's strategy to achieve broader healthcare community adoption and increase unit sales of their Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices.
NanoVibronix (NASDAQ: NAOV) has successfully completed the pilot phase of a Randomized Control Trial study for UroShield® at the University of Michigan. The study, primarily conducted with nursing home residents, focused on evaluating UroShield's impact on reducing urinary tract infections, catheter blockages, and pain associated with long-term urinary catheter use.
The completed pilot phase served as a validation step before advancing to the full study, which is expected to commence in 2025. The research team has achieved their initial goals, including refining recruitment strategies and developing data collection tools. This research complements previous studies and product launches in the UK, Australia, and New Zealand, as well as the recent introduction to the European market. The company is simultaneously preparing for a U.S. launch, pending FDA 510K clearance.
NanoVibronix (NASDAQ: NAOV) has renewed its exclusive distribution agreement with Ultra Pain Products (UPPI) for PainShield distribution for another five years. The agreement includes a minimum purchase commitment of $12 million. The renewal follows UPPI's significant growth over the past four years and its evolution in the non-opioid pain management and injury recovery industry.
The collaboration aims to strengthen both companies' market presence, with UPPI continuing to distribute NanoVibronix's proprietary PainShield as part of its expanding portfolio of technologies. The partnership focuses on providing innovative non-opioid treatment options while prioritizing safety, efficacy, and accessibility in the U.S. market.
NanoVibronix, a medical device company, provided a business update highlighting recent developments. CEO Brian Murphy emphasized progress in expanding distribution, raising commercial awareness, and pursuing reimbursements. The company's products, including UroShield®, PainShield®, and WoundShield®, continue to show high patient satisfaction.
The company signed a letter of intent with Kriel Technology Group to explore UroShield distribution in South Africa, with a market evaluation planned for early next year. Independent research presented at major medical conferences demonstrated UroShield's effectiveness in reducing catheter-associated urinary tract infections (CAUTIs).
Reimbursement efforts include a successful application for UroShield actuators on NHS Prescription Services' Drug Tariff and ongoing submissions for full reimbursement in the UK and Germany. The company remains optimistic about expanding its market presence and increasing product awareness globally.
NanoVibronix (NASDAQ: NAOV) has signed a non-binding term sheet for a license and supply agreement with APOGEPHA Arzneimittel GmbH, a German pharmaceutical company specializing in urology products. The agreement aims to distribute UroShield throughout Europe. UroShield is an ultrasound-based device designed to prevent bacterial colonization and biofilm on indwelling urinary catheters, potentially reducing catheter-associated urinary tract infections (CAUTI) and associated pain.
Brian Murphy, CEO of NanoVibronix, expressed enthusiasm about partnering with APOGEPHA, citing their leadership in urology and large sales and marketing team as key factors for accelerating UroShield sales in Germany. Dr. Dirk Pamperin, Chairman of APOGEPHA's Management Board, stated their commitment to offering high-quality urological products and their confidence in UroShield's ability to support patients with long-term catheters.
